NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) arising in nonalcoholic fatty liver disease (NAFLD) may not be suitable for systemic therapy due to metabolic syndrome-related diseases. Recent trials did not show a survival benefit of radioembolization (RE) compared to sorafenib in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Cancer
Main Authors: Schotten, Clemens, Bechmann, Lars P., Manka, Paul, Theysohn, Jens, Dechêne, Alexander, El Fouly, Amr, Barbato, Francesco, Neumann, Ursula, Radünz, Sonia, Sydor, Svenja, Heider, Dominik, Venerito, Marino, Canbay, Ali, Gerken, Guido, Herrmann, Ken, Wedemeyer, Heiner, Best, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2019
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883476/
https://ncbi.nlm.nih.gov/pubmed/31799206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501484
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados